News Daily News Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM Caitlin E. Cox March 21, 2025
News Daily News REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF Michael O'Riordan March 11, 2025
News Daily News Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF Michael O'Riordan March 03, 2025
News Daily News Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time Michael O'Riordan February 13, 2025
News Conference News THT 2025 AIM-POWER: Remote, App-Based Intervention Boosts GDMT Use in HFrEF Todd Neale February 13, 2025
News Conference News THT 2025 Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity Todd Neale February 12, 2025
News Daily News Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3 Yael L. Maxwell January 15, 2025
News Daily News Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit Michael O'Riordan January 13, 2025
News Daily News FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity L.A. McKeown December 13, 2024
News Daily News Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT L.A. McKeown December 05, 2024
News Daily News FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy L.A. McKeown November 25, 2024
News Conference News AHA 2024 REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients L.A. McKeown November 22, 2024
Presentation AHA 2024 Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial Presenter: Milton Packer November 16, 2024
News Conference News AHA 2024 Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F Michael O'Riordan November 16, 2024
News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024